UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000031406
Receipt No. R000035858
Scientific Title Clinical study on iron absorption after oral administration of ferric citrate hydrate - Riona-Oral Iron Absorption Trial (R-OIAT)-
Date of disclosure of the study information 2018/02/21
Last modified on 2018/02/21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Clinical study on iron absorption after oral administration of ferric citrate hydrate - Riona-Oral Iron Absorption Trial (R-OIAT)-
Acronym R-OIAT
Scientific Title Clinical study on iron absorption after oral administration of ferric citrate hydrate - Riona-Oral Iron Absorption Trial (R-OIAT)-
Scientific Title:Acronym R-OIAT
Region
Japan

Condition
Condition Hemodialysis patients
Classification by specialty
Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To clarify the association with serum hepcidine-25 and absorption of iron
Basic objectives2 Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes 1) serum Hepcidine-25
2) serum iron
(first visit, 3month, 6month)
Key secondary outcomes 1) UIBC
2) serum ferritin
( first visit, 3month, 6month)

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Maintenance hemodialysis patients
2) Given informed consent
3) Agree to contraception during the study
Key exclusion criteria 1) infectious disease
2) malignancy
3) pregnancy
Target sample size 4000

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Naohisa Tomosugi
Organization Kanazawa Medical University
Division name Medical Research Institute , Division of Systems Bioscience for Drug Discovery Based on Intrinsically Disordered Proteins
Zip code
Address 1-1 Daigaku, Uchinaka-machi, Kahoku-gun, Ishikawa-ken 920-0293, Japan
TEL 076-286-2211
Email tomosugi@kanazawa-med.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Naohisa Tomosugi
Organization Kanazawa Medical University
Division name Medical Research Institute , Division of Systems Bioscience for Drug Discovery Based on Intrinsicall
Zip code
Address 1-1 Daigaku, Uchinaka-machi, Kahoku-gun, Ishikawa-ken 920-0293, Japan
TEL 076-286-2211
Homepage URL
Email tomosugi@kanazawa-med.ac.jp

Sponsor
Institute Kanazawa Medical University
Institute
Department

Funding Source
Organization Kanazawa Medical University
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s) TORII PHARMACEUTICAL CO., LTD.

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 02 Month 21 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2016 Year 07 Month 25 Day
Date of IRB
Anticipated trial start date
2016 Year 07 Month 27 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Hemodialysis patients who initiate ferric citrate hydrate or under treatment with ferric citrate hydrate after meal will be enrolled. Patients will be treated with ferric citrate hydrate after the start of a hemodialysis session on first visit, 3 month and 6 month.

Management information
Registered date
2018 Year 02 Month 21 Day
Last modified on
2018 Year 02 Month 21 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035858

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.